An established show has several new programs that reflect the industry's current challenges.
In addition to showcasing the latest innovations in pharmaceutical manufacturing equipment, INTERPHEX 2010 will help attendees stay current through various new presentations and discussions. Pharmaceutical Technology is partnering with INTERPHEX to present speakers from the US Food and Drug Administration, Rx–360, and PharmSource, a provider of business intelligence. Conference visitors will hear representatives of these groups discuss deficiencies in new drug applications, trends in supply-chain security, and the state of the outsourcing industry. Best of all, the speakers will take time to answer questions from the audience.
Erik Greb
Although INTERPHEX is associated with small-molecule manufacturing, the conference is broadening its offerings for professionals involved in large-molecule production. BioPharm International, our sister publication, organized the keynote presentation this year about the effect of healthcare reform on the biopharmaceutical industry. MSNBC's Chris Matthews will moderate the discussion.
And each day, my colleagues and I will be conducting live interviews with various industry experts. We'll be giving you the scoop about quality-by-design implementation, packaging innovations, harmonization, and high-potency drugs. Our interviews will be videotaped and featured on our website after the conference.
INTERPHEX 2010 promises to keep attendees informed about the latest trends and innovations shaping the drug industry. I hope to see you there!
Check out PharmTech's preliminary program for its live video interviews at Interphex 2010
Erik Greb is an assistant editor of Pharmaceutical Technology.
» Read Erik's blogs at blog.PharmTech.com.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.